Table 2.
Effect of human serum albumin on embryo development
| Recombinant HSA | Vitrolife HSA | Sage HSA | |
|---|---|---|---|
| 48-h culture (day 3) | |||
| < 8cell (delayed) (%) | 70.0 | 65.0 | 73.0 |
| 8 cell (%) | 17.0a | 19.0a | 12.0b |
| Compacting (%) | 8.0 | 12.0 | 12.0 |
| 72-h culture (day 4) | |||
| Morula (%) | 31.4 | 35.0 | 32.3 |
| Early blastocyst (%) | 10.2a | 13.2ab | 18.2b |
| Blastocyst (%) | 18.1a | 17.5a | 11.4b |
| Expanded and hatching blastocyst (%) | 15.7 | 17.8 | 16.2 |
Embryo development data is expressed as percentage of presumptive zygote that reached each development stages. N = 361, 355, and 347 embryos for Recombinant, Vitrolife, and Sage HSA respectively (15 replicate experiments). Different superscript letters denote significance between treatment groups within a row (P < 0.05). HSA human serum albumin